Table 3.
Ongoing clinical trials by KGOG in 2024.
| Protocol | Study Title | KGOG-Led or Participated | CRIS ID/ ClinicalTrials.gov ID |
|---|---|---|---|
| Cervix, Vulva, Vagina TSC | |||
| KGOG 1028s | Radiotherapy versus observation in intermediate risk patients after radical hysterectomy for early cervical cancer (R-OBERV): Ancillary analysis of a Korean Gynecologic Group Study | KGOG-Led | -/- |
| KGOG 1036 | A PROBE (prospective specimen collection and retrospective blinded evaluation) study of HPV viral load to improve cervical cancer screening | KGOG-Led | KCT0009466/ - |
| KGOG 1038 | Phase II study of Belotecan monotherapy in patients with recurrent or persistent cervical cancer | KGOG-Led | KCT0004484/ - |
| KGOG 1046 | AFTER trial: Adjuvant chemotherapy vs. radiotherapy for postoperative cervicalcancer—A Phase III trial | Participated | KCT0006893/ - |
| KGOG 1047 | Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer Stage IIICr: A Phase III, randomized controlled clinical trial (DEBULK trial) | KGOG-Led | KCT0007137/ NCT05421650 |
| KGOG 1049 | GOG-3043: A randomized controlled trial of robotic versus open radical hysterectomy for cervical cancer (ROCC trial) | Participated | KCT0009284/ NCT04831580 |
| Uterine Corpus-GTT TSC | |||
| KGOG 2020 | Phase II study of fertility-sparing management using high-dose oral progestin in young women with Stage I endometrial adenocarcinoma with grade 2 differentiation or superficial myometrial invasion | KGOG-Led | KCT0003226/ NCT03567655 |
| KGOG 2024 | Phase 2 trial for chemo-resistant gestational trophoblastic neoplasias with Pembrolizumab (CR-GTP) | KGOG-Led | KCT0005469/ NCT04303884 |
| KGOG 2029 | Randomized comparison between sentinel lymph node mapping and lymph node dissection in early-stage endometrial cancer | KGOG-Led | KCT0006852/ NCT04845828 |
| KGOG 2030 | Development of biomarker predicting high-dose progesterone therapy in reproductive aged women with early-stage endometrial cancer | KGOG-Led | -/- |
| KGOG 2031 | A Phase II trial evaluating the efficacy and safety of repeated high-dose MPA therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia | Participated | jRCTs031200256 * |
| KGOG 2034 | Pelvic and para-aortic lymphadenectomy in patients with Stage I or II endometrial cancer with high risk of recurrence (ECLAT; AGO-OP.6); a multi-center, prospective randomized controlled trial | Participated | KCT0004981/ NCT03438474 |
| KGOG 2035 | A Phase II/III study of Paclitaxel/Carboplatin alone or combined with either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2-positive, Stage I-IV endometrial serous carcinoma or carcinosarcoma | Participated | KCT0009300/ NCT05256225 |
| Ovary–Fallopian tube TSC | |||
| KGOG 3033 | Prospective study evaluating a strategy of surgery alone and surveillance in FIGO Stage I malignant ovarian germ cell tumor | KGOG-Led | -/- |
| KGOG 3050 | Laparoscopic/robotic vs. open surgery in the treatment of apparently early-stage epithelial ovarian cancer | KGOG-Led | -/- |
| KGOG 3051 | NRG-GY019: A randomized Phase III, two-arm trial of Paclitaxel/Carboplatin/maintenance Letrozole versus Letrozole monotherapy in patients with Stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum | Participated | KCT0005153/ NCT04095364 |
| KGOG 3053 | NRG CC-008 clinical trial: A non-randomized prospective clinical trail comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROC) | Participated | KCT0007701/ NCT04251052 |
| KGOG 3055 | JGOG3024: Prospective cohort study of variant carriers with BRCA1 and BRCA2 | Participated | -/ NCT03296826 |
| KGOG 3058 | ESPOIR: Effectiveness and safety of PARP-inhibitor therapy in recurrent ovarian cancer patients in the real world; Ambidirectional multi-center cohort study | Participated | -/- |
| KGOG 3059 | PMFO: A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/fallopian/peritoneal cancer | Participated | -/- |
| KGOG 3060 | Effectiveness of routine intensive CA125 monitoring in ovarian cancer: A pragmatic randomized study | KGOG-Led | KCT0007454/ - |
| KGOG 3062 | Phase III randomized clinical trial for Stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-2) | Participated | -/ NCT03772028 |
| KGOG 3064 | Prospective multi-institutional Phase III trial of salvage systemic therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC) | KGOG-Led | KCT0007950/ NCT05444270 |
| KGOG 3066 | A multi-center, open-label, single-arm, Phase II study to evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in platinum-resistant, advanced/relapsed ovarian cancer patients previously treated with a PARP inhibitor | Participated | -/ NCT05475184 |
| KGOG 3067 | A randomized Phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (SOCCER-P) | KGOG-Led | KCT0008662/ - |
| Surgery, Developmental Diagnostic, and Therapeutics (DDT) Committee | |||
| KGOG 4005 | The analysis of the patients who have received reoperation within 30 days after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer | KGOG-Led | -/- |
| KGOG 4006 | The analysis of 90-day postoperative mortality after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer | KGOG-Led | -/- |
| KGOG 4007 | Effective drug therapy for recurrent ovarian clear cell carcinoma | KGOG-Led | -/- |
| KGOG 4008 | Study on the clinical utility of circulating tumor DNA methylation in the screening of uterine and ovarian cancers (CIRCUS) | KGOG-Led | -/- |
| KGOG 4009 | Efficacy and safety evaluation of advanced vessel sealing device (Vi-sealer) | KGOG-Led | KCT0008008/ NCT05629611 |
| KGOG 4010 | Assessment of quality of life after low anterior resection or visceral peritoneal stripping during cytoreductive surgery for advanced ovarian cancer requiring tumor resection on the rectosigmoid colon: a prospective cohort study | KGOG-Led | -/ NCT05431530 |
| KGOG 4011 | A prospective randomized controlled trial evaluating the safety and efficacy of patient blood management program in patients with gynecologic cancer | KGOG-Led | -/ NCT05669872 |
* Japan Registry of Clinical Trials.